Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Identification and immunotherapeutic targeting of antigens induced by chemotherapy

Abstract

Cancer cells differ from normal cells in their response to chemotherapy. We exploited this dissimilarity by identifying and targeting tumor-specific, cell-surface proteins whose expression is induced by the chemotherapeutic irinotecan (CPT-11; Camptosar). A cytotoxin-armed antibody reactive with one of these drug-induced surface proteins, the LY6D/E48 antigen, originally identified as the target of a monoclonal antibody reactive with squamous cell carcinomas, caused complete regression of colorectal tumor xenografts in mice treated with CPT-11, whereas either agent alone was less effective. These results suggest that a positive therapeutic index may be generated for other drug combinations by immunotherapeutic targeting of chemotherapy-induced antigens.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: mRNA transcripts coding for cell-surface proteins induced by CPT-11.
Figure 2: Expression of mouse intestinal transcripts homologous to those induced in human tumor xenografts.
Figure 3: Induction of cell-surface reactive LY6D/E48 protein in vitro by CPT-11 and SN-38.
Figure 4: Anti-tumor activity of CPT-11 combined with anti-LY6D/E48-drug conjugate.

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Tice, D.A. et al. Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J. Biol. Chem. 277, 14329–14335 (2002).

    Article  CAS  Google Scholar 

  2. Mehta, K., Ocanas, L., Malavasi, F., Marks, J.W. & Rosenblum, M.G. Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells. Mol. Cancer Ther. 3, 345–352 (2004).

    CAS  PubMed  Google Scholar 

  3. Qin, L.F., Lee, T.K. & Ng, I.O. Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. Life Sci. 70, 1677–1690 (2002).

    Article  CAS  Google Scholar 

  4. Li, Y. et al. Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 5, 7 (2005).

    Article  Google Scholar 

  5. Whiteside, M.A., Chen, D.T., Desmond, R.A., Abdulkadir, S.A. & Johanning, G.L. A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene 23, 744–752 (2004).

    Article  CAS  Google Scholar 

  6. Chang, B.D. et al. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc. Natl. Acad. Sci. USA 99, 389–394 (2002).

    Article  CAS  Google Scholar 

  7. Taxman, D.J., MacKeigan, J.P., Clements, C., Bergstralh, D.T. & Ting, J.P. Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor. Cancer Res. 63, 5095–5104 (2003).

    CAS  PubMed  Google Scholar 

  8. Zhou, Y. et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 62, 1688–1695 (2002).

    CAS  PubMed  Google Scholar 

  9. Kudoh, K. et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60, 4161–4166 (2000).

    CAS  PubMed  Google Scholar 

  10. Macdonald, J.S. Clinical overview: adjuvant therapy of gastrointestinal cancer. Cancer Chemother. Pharmacol. 54. (Suppl 1), S4–11 (2004).

    CAS  PubMed  Google Scholar 

  11. Brakenhoff, R.H. et al. The human E48 antigen, highly homologous to the murine Ly-6 antigen ThB, is a GPI-anchored molecule apparently involved in keratinocyte cell-cell adhesion. J. Cell Biol. 129, 1677–1689 (1995).

    Article  CAS  Google Scholar 

  12. de Bree, R. et al. Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients. Br. J. Cancer 75, 1049–1060 (1997).

    Article  CAS  Google Scholar 

  13. de Bree, R., Roos, J.C., Verel, I., van Dongen, G.A. & Snow, G.B. Radioimmunodiagnosis of lymph node metastases in head and neck cancer. Oral Dis. 9, 241–248 (2003).

    Article  CAS  Google Scholar 

  14. Nieuwenhuis, E.J. et al. Assessment and clinical significance of micrometastases in lymph nodes of head and neck cancer patients detected by E48 (Ly-6D) quantitative reverse transcription-polymerase chain reaction. Lab. Invest. 83, 1233–1240 (2003).

    Article  CAS  Google Scholar 

  15. Oosterhoff, D. et al. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol. Cancer Ther. 2, 765–771 (2003).

    CAS  PubMed  Google Scholar 

  16. Bevins, C.L. The Paneth cell and the innate immune response. Curr. Opin. Gastroenterol. 20, 572–580 (2004).

    Article  Google Scholar 

  17. Doronina, S.O. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21, 778–784 (2003).

    Article  CAS  Google Scholar 

  18. Brakenhoff, R.H., van Dijk, M., Rood-Knippels, E.M. & Snow, G.B. A gain of novel tissue specificity in the human Ly-6 gene E48. J. Immunol. 159, 4879–4886 (1997).

    CAS  PubMed  Google Scholar 

  19. Quak, J.J. et al. A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. Am. J. Pathol. 136, 191–197 (1990).

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Eshel, R. et al. The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells. J. Biol. Chem. 275, 12833–12840 (2000).

    Article  CAS  Google Scholar 

  21. Eshel, R. et al. Human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head-and-neck squamous carcinoma cells. Int. J. Cancer 98, 803–810 (2002).

    Article  CAS  Google Scholar 

  22. Wodicka, L., Dong, H., Mittmann, M., Ho, M.H. & Lockhart, D.J. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat. Biotechnol. 15, 1359–1367 (1997).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Peter Senter and Damon Meyer for preparation of drug-conjugated antibodies, Tracey McKenna, Angela Lamb, JoAnne Hongo and Kurt Schroeder for generation and purification of monoclonal antibodies to LY6D/E48 and technical assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul Polakis.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Table 1

Transcripts induced in Colo205 tumor xenografts exposed to CPT-11. (PDF 51 kb)

Supplementary Table 2

Transcripts induced in the intestine of mice exposed to CPT-11. (PDF 46 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rubinfeld, B., Upadhyay, A., Clark, S. et al. Identification and immunotherapeutic targeting of antigens induced by chemotherapy. Nat Biotechnol 24, 205–209 (2006). https://doi.org/10.1038/nbt1185

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1185

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing